1. Scrip
  2. >>Focus On Asia

ASCO: GenFleet’s KRAS G12C/EGFR Combo Sets Sail In First-Line NSCLC

IO, Chemo-Free Strategy

 
• By Dexter Jie Yan

Excluding PD-1 inhibitors in its combination strategy for oncology, preliminary results from GenFleet’s Phase II KROCUS study presented at ASCO demonstrate promising efficacy for fulzerasib plus cetuximab in the first-line treatment of KRAS G12C-mutated, advanced non-small cell lung cancer.

set sail
GenFleet sets sail in first-line KRAS G12C-mutated NSCLC with novel combo strategy excluding PD-1s • Source: Shutterstock

Amid the global race to scour for the best partners and approaches for KRAS G12C inhibitors for the first-line treatment of advanced non-small cell lung cancer (NSCLC) harboring the hard-to-drug mutation, Chinese biotech GenFleet Therapeutics has conjured up an immunotherapy- or chemotherapy-free strategy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia